Promising drug for kids with rare muscle disease moves to next phase

NCT ID NCT06055959

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 22 times

Summary

This study is testing a drug called zilucoplan in children aged 2 to 17 who have generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug works in the body, how safe it is, and if it helps control the disease. Only 8 children will take part, and they will receive the drug without a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Mg0014 20104
RECRUITING

Seoul, South Korea
Mg0014 20220
RECRUITING

Seoul, South Korea
Mg0014 40144
RECRUITING

Milan, Italy
Mg0014 40218
ACTIVE_NOT_RECRUITING

Warsaw, Poland
Mg0014 40735
RECRUITING

Glasgow, United Kingdom
Mg0014 40736
RECRUITING

London, United Kingdom
Mg0014 40774
RECRUITING

Katowice, Poland
Mg0014 50168
WITHDRAWN

Chicago, Illinois, 60611, United States
Mg0014 50574
WITHDRAWN

Denton, Texas, 76208, United States

Conditions

Explore the condition pages connected to this study.

GENERALIZED MYASTHENIA GRAVIS